66-year-old woman with painless jaundice.

N. Gentile,A. Greenlund

DOI: https://doi.org/10.1016/j.mayocp.2012.03.018

IF: 11.104

2012-10-01

Mayo Clinic Proceedings

Abstract:

What problem does this paper attempt to address?

Postprandial platelet aggregation: effects of different meals and glycemic index

K D K Ahuja,G A Thomas,M J Adams,M J Ball

DOI: https://doi.org/10.1038/ejcn.2012.28

2012-03-21

European Journal of Clinical Nutrition

Abstract:Background/Objectives:Hyperglycaemia is associated with increased platelet aggregation that increases the risk of thrombosis in people with type-2 diabetes and cardiovascular disease. Low glycemic index (GI) meals high in carbohydrate or moderately high in protein have been shown to acutely reduce postprandial excursions of plasma glucose and insulin compared with high carbohydrate high GI meals. However, it is not known whether these differences in glucose and insulin profile also impact on postprandial platelet aggregation. This study aimed to investigate the acute effects of three iso-energetic meals, on measures of postprandial platelet aggregation, in healthy individuals.Subjects/Methods:A randomised cross-over study compared the acute effects of a high GI high carbohydrate (HGI-HC), a low GI high carbohydrate (LGI-HC) and a low GI moderately high in protein and fat (LGI-MPF) meal on postprandial platelet aggregation, glucose, insulin and triglyceride concentrations. Comparisons were made at fasting, 60 and 120 min postprandially.Results:A total of 32 volunteers (mean±s.d.; age 59.9±11.7 years, BMI 27.1±3.7 kg/m2) participated in the study. Results showed significant reductions in maximum platelet aggregation postprandially with nonsignificant differences (all P>0.29) between the three meals. Glucose and insulin were significantly (both P<0.001) higher at 60 min postprandially on the HGI-HC meal compared with both LGI-HC and LGI-MPF meals. Triglycerides were not significantly different (all P>0.25) between the three test meals.Conclusion:In healthy individuals platelet aggregation is reduced postprandially but this decrease is similar between meals of different GI that induce different glucose and insulin responses.

nutrition & dietetics
Effects of insulin on platelet and leukocyte activity in whole blood.

Hu Hu,Paul Hjemdahl,Nailin Li

DOI: https://doi.org/10.1016/S0049-3848(02)00306-7

IF: 10.407

2002-01-01

Thrombosis Research

Abstract:Diabetes mellitus (DM) is associated with platelet and leukocyte dysfunction. Previous observations with regard to insulin effects on platelet and leukocyte function are less than consistent. We thus investigated the effects of insulin on platelets and leukocytes, as well as on platelet–leukocyte interactions in whole blood. Hirudinized whole blood from 20 healthy subjects was preincubated at 37 °C in the absence or presence of insulin (30 and 300 μU/ml), and further incubated without or with adenosine diphosphate (ADP) (10−5 M) or N-formyl-methionyl-leucyl-phenylalanine (fMLP) (10−7 M), respectively. Platelet P-selectin expression, platelet fibrinogen binding, single platelet and platelet–platelet aggregate (PPA) counts, and leukocyte CD11b expression and superoxide anion production were monitored by flow cytometry. Insulin decreased single platelet counts (P<0.05) and increased PPAs (P<0.01) at 300 μU/ml in unstimulated samples, but did not significantly influence the P-selectin expression or fibrinogen binding of single platelets. Insulin also enhanced ADP-induced platelet aggregation, seen as an augmented decrease of single platelet counts. Insulin (30 μU/ml) increased leukocyte CD11b mean fluorescence intensity (MFI) in unstimulated, as well as fMLP- and ADP-stimulated samples (P<0.05 for all). fMLP-induced superoxide anion (O2−) production was, however, attenuated by insulin. Furthermore, fMLP-activation of leukocytes was associated with enhanced platelet fibrinogen binding and P-selectin expression. In conclusion, clinically relevant concentrations of insulin enhance platelet aggregability and leukocyte CD11b expression, but attenuate leukocyte respiratory burst activity. Our results suggest that insulin may modulate thrombotic and inflammatory processes in vivo in a complex manner.
The Effect of Hyperglycaemia on the Islet Β-Cell Responsiveness in Type 2 Diabetic Patients

胡肇衡,高月琴,卢纹凯,纪立农

DOI: https://doi.org/10.3321/j.issn:1006-6187.2004.04.003

2004-01-01

Abstract:Objective To evaluate the effect of chronic hyper glycaemia on the pancreatic β-cell response in diabetic patients. Me thods We investigated the effect of various blood glucose levels on the β-cell response to stimulation with a standard oral glucose or intravenous gl ucagon in 118 patients with type 2 diabetes. Results The rele ases of C-peptide and insulin were decreased with increased level of fasting blood glucose (P0.01)after oral glucose stimulation, and were increased with decreased levels of fasting blood glucose after glucagon stimulation wh ile C-peptide and insulin release keeping higher when fasting blood glucose lev el was above 9 mmol/L. The release of insulin showed an inverse association to HOMA-IR (P0.01)after oral glucose stimulation and it showed a positive association with HOMA-β(P0.01)after glucagon stimulation. C onclusions The evaluation of function of β-cell secretion is confused by glucose toxicity because severe hyperglycaemia significantly reduces C-pep tide and insulin release after oral glucose stimulation, but this is not the cas e after glucagon stimulation in type 2 diabetic patients.
A randomised controlled study of high intensity exercise as a dishabituating stimulus to improve hypoglycaemia awareness in people with type 1 diabetes: a proof-of-concept study

Catriona M Farrell,Alison D McNeilly,Paul Fournier,Timothy Jones,Simona M Hapca,Daniel West,Rory J McCrimmon

DOI: https://doi.org/10.1007/s00125-019-05076-5

IF: 8.2

Diabetologia

Abstract:Aims/hypothesis: Approximately 25% of people with type 1 diabetes have suppressed counterregulatory hormonal and symptomatic responses to insulin-induced hypoglycaemia, which renders them at increased risk of severe, disabling hypoglycaemia. This is called impaired awareness of hypoglycaemia (IAH), the cause of which is unknown. We recently proposed that IAH develops through habituation, a form of adaptive memory to preceding hypoglycaemia. Consistent with this hypothesis, we demonstrated restoration of defective counterregulatory hormonal responses to hypoglycaemia (referred to as dishabituation) in a rodent model of IAH following introduction of a novel stress stimulus (high intensity training [HIT]). In this proof-of-concept study we sought to further test this hypothesis by examining whether a single episode of HIT would amplify counterregulatory responses to subsequent hypoglycaemia in people with type 1 diabetes who had IAH (assessed by Gold score ≥4, modified Clarke score ≥4 or Dose Adjustment For Normal Eating (DAFNE) hypoglycaemia awareness rating 2 or 3). The primary outcome was the difference in adrenaline response to hypoglycaemia following both a single episode of HIT and rest. Methods: In this randomised, crossover study 12 participants aged between 18 and 55 years with type 1 diabetes for ≥5 years and an HbA1c <75 mmol/mol (9%) were recruited. Individuals were randomised using computer generated block randomisation to start with one episode of HIT (4 × 30 s cycle sprints [2 min recovery] at 150% of maximum wattage achieved during [Formula: see text] assessment) or rest (control). The following day they underwent a 90 min hyperinsulinaemic-hypoglycaemic clamp study at 2.5 mmol/l with measurement of hormonal counterregulatory response, symptom scores and cognitive testing (four-choice reaction time and digit symbol substitution test). Each intervention and subsequent clamp study was separated by at least 2 weeks. The participants and investigators were not blinded to the intervention or measurements during the study. The investigators were blinded to the primary outcome and blood analysis results. Results: All participants (six male and six female, age 19-54 years, median [IQR] duration of type 1 diabetes 24.5 [17.3-29.0] years, mean [SEM] HbA1c 56 [3.67] mmol/mol; 7.3% [0.34%]) completed the study (both interventions and two clamps). In comparison with the rest study, a single episode of HIT led to a 29% increase in the adrenaline (epinephrine) response (mean [SEM]) (2286.5 [343.1] vs 2953.8 [384.9] pmol/l); a significant increase in total symptom scores (Edinburgh Hypoglycaemia Symptom Scale: 24.25 [2.960 vs 27.5 [3.9]; p<0.05), and a significant prolongation of four-choice reaction time (591.8 [22.5] vs 659.9 [39.86] ms; p<0.01] during equivalent hypoglycaemia induced the following day. Conclusions/interpretation: These findings are consistent with the hypothesis that IAH develops in people with type 1 diabetes as a habituated response and that introduction of a novel stressor can restore, at least partially, the adapted counterregulatory hormonal, symptomatic and cognitive responses to hypoglycaemia. Trial registration: ISRCTN15236211.
Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

A Ranjan,S Schmidt,S Madsbad,J J Holst,K Nørgaard

DOI: https://doi.org/10.1111/dom.12627

Abstract:Aim: To investigate the dose-response relationship of subcutaneous (s.c.) glucagon administration on plasma glucose and on counter-regulatory hormone responses during s.c. insulin-induced mild hypoglycaemia in patients with type 1 diabetes treated with insulin pumps. Methods: Eight insulin pump-treated patients completed a blinded, randomized, placebo-controlled study. Hypoglycaemia was induced in the fasting state by an s.c. insulin bolus and, when plasma glucose reached 3.4 mmol/l [95% confidence interval (CI) 3.2-3.5], an s.c. bolus of either 100, 200, 300 µg glucagon or saline was administered. Plasma glucose, counter-regulatory hormones, haemodynamic variables and side effects were measured throughout each study day. Peak plasma glucose level was the primary endpoint. Results: Plasma glucose level increased significantly by a mean (95% CI) of 2.3 (1.7-3.0), 4.2 (3.5-4.8) and 5.0 (4.3-5.6) mmol/l to 6.1 (4.9-7.4), 7.9 (6.4-9.3) and 8.7 (7.8-9.5) vs 3.6 (3.4-3.9) mmol/l (p < 0.001) after the three different glucagon doses as compared with saline, and the increase was neither correlated with weight nor insulin levels. Area under the plasma glucose curve, peak plasma glucose, time to peak plasma glucose and duration of plasma glucose level above baseline were significantly enhanced with increasing glucagon doses; however, these were not significantly different between 200 and 300 µg glucagon. Free fatty acids and heart rates were significantly lower initially after glucagon than after saline injection. Other haemodynamic variables, counter-regulatory hormones and side effects did not differ between interventions. Conclusions: An s.c. low-dose glucagon bolus effectively restores plasma glucose after insulin overdosing. Further research is needed to investigate whether low-dose glucagon may be an alternative treatment to oral carbohydrate intake for mild hypoglycaemia in patients with type 1 diabetes.
Type 2 Diabetes: Platelets and Long-Term Metabolic Control as Estimated from Glycosylated Haemoglobin (HbA1c)

M. Edvardsson,M. Oweling,P. Järemo,Järemo,P.

DOI: https://doi.org/10.1055/s-0044-1780535

2024-03-07

Hämostaseologie

Abstract:In type 2 diabetes, platelets are likely affected by impaired long-term glycaemic control, but such pathophysiological links are poorly understood. This study thus compares platelet reactivity (i.e. agonist-evoked platelet reactions) in vitro with glycosylated haemoglobin (HbA1c), a measure commonly used for monitoring long-term metabolic control of type 2 diabetes. Elders with type 2 diabetes ( n = 35) were divided according to HbA1c into groups (HbA1c—low and high) consisting of 17 and 18 subjects, respectively. For estimating mitochondria disintegration, a flow cytometer determined mitochondrial transmembrane potentials after whole blood agonist stimulation. The activating agents used were α-thrombin (10 μM) and collagen (0.15 μg/mL). The same apparatus analysed the fibrinogen receptor activity, lysosomal exocytosis (surface lysosomal-associated membrane protein 1), and platelet procoagulant characteristics (membrane-attached annexin V) after stimulation. In type 2 diabetes, after in vitro agonist stimulation, platelet mitochondria injury was higher in the HbA1c-high group. The fibrinogen receptor, lysosomal secretion, and the creation of procoagulant platelets proved to be uninfluenced by HbA1c. Data are available from the corresponding author upon reasonable request. M.E.: Conceived the research, performed sample and data collection, and did the practical flow cytometry work. M.O.: Formulated and partly financed the investigation and supervised its findings. P.J.: Devised and partially financed the study, carried out data analysis, and wrote the first draft of the manuscript. Subsequently, all authors revised the manuscript critically for intellectual content. Received: 07 October 2023 Accepted: 08 January 2024 Article published online: 06 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Stuttgart · New York

hematology
Epidemiology of chronic pain and critical issues on opioid use

P. Sjøgren

DOI: https://doi.org/10.1016/j.pain.2011.03.005

IF: 7.926

2011-06-01

Pain

Abstract:
Real‐life hypoglycaemia partially blunts the inflammatory response to experimental hypoglycaemia in people with type 1 diabetes

Mandala Ajie,Julia I. P. van Heck,Clementine E. M. Verhulst,Therese W. Fabricius,Marijn S. Hendriksz,Rory J. McCrimmon,Ulrik Pedersen‐Bjergaard,Bastiaan de Galan,Rinke Stienstra,Cees J. Tack

DOI: https://doi.org/10.1111/dom.15712

2024-06-22

Diabetes Obesity and Metabolism

Abstract:Aim To determine whether recent repeated exposure to real‐life hypoglycaemia affects the pro‐inflammatory response during a hypoglycemia episode. Materials and Methods This was a post hoc analysis of a hyperinsulinaemic normoglycaemic‐hypoglycaemic clamp study, involving 40 participants with type 1 diabetes. Glucose levels 1 week before the clamp were monitored using a Freestyle Libre 1. Blood was drawn during normoglycaemia and hypoglycaemia, and 24 hours after resolution of hypoglycaemia for measurements of inflammatory responses and counterregulatory hormone levels. We determined the relationship between the frequency and duration of spontaneous hypoglycaemia, and time below range (TBR) and the inflammatory response to experimental hypoglycaemia. Results On average, participants experienced 0.79 (0.43, 1.14) hypoglycaemia episodes per day, with a duration of 78 (47, 110) minutes and TBR of 5.5% (2.8%, 8.5%). TBR and hypoglycaemia frequency were inversely associated with the increase in circulating granulocyte and lymphocyte counts during experimental hypoglycaemia (P

endocrinology & metabolism
Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]

B. Shenkman,Y. Einav,O. Salomon,D. Varon,N. Savion

DOI: https://doi.org/10.1080/09537100802082256

2008-01-01

Platelets

Abstract:The Impact-R [Cone and plate(let) analyzer (CPA)] is useful to assess platelet adhesion in different diseases and to monitor antiplatelet therapy. The purpose of the present study was to adapt this system to test agonist-induced platelet aggregation. Blood samples were tested by light transmission platelet aggregometry (LTA), Impact-R regular test and Impact-R agonist-response test. In the latter, samples were pre-incubated for 1 min with an agonist leading to platelet activation, micro-aggregates formation and reduced adhesion. Impact-R regular test of ten healthy volunteers demonstrated platelet adhesion (surface coverage, SC) of 11.2 +/- 2.6% while LTA induced by ADP, ristocetin, epinephrine, collagen and arachidonic acid (AA) yielded maximal aggregation (81% to 93%). In the Impact-R agonist-response test, SC was reduced to 2.2 +/- 1.0%, 1.2 +/- 0.9%, 2.3 +/- 1.0%, 2.2 +/- 0.8% and 2.4 +/- 0.4%, respectively. Prostaglandin E(1) treatment weakened SC reduction in response to ADP and epinephrine (SC of 8.8 +/- 1.8% and 9.5 +/- 2.0%, respectively). Inhibition of P2Y(12) receptor with 2MeSAMP resulted in a dose-dependent decrease in maximal aggregation in the ADP-induced test, which inversely correlated to SC in the Impact-R ADP-response test. The Impact-R agonist-response tests detected aggregation defects in patients with storage pool disease, severe von Willebrand disease and epinephrine response deficiency, and may be useful to assess the effect of different agonists on platelet aggregation.

cell biology,hematology
Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers

Manjula Nandakumar,Thozhukat Sathyapalan,Stephen L. Atkin,Alexandra E. Butler

DOI: https://doi.org/10.3390/biomedicines12061137

IF: 4.757

2024-05-22

Biomedicines

Abstract:Introduction: Hypoglycemia has been associated with cardiovascular events, and glucose variability has been suggested to be associated with increased cardiovascular risk. Therefore, in this study, we examined the effect on proteomic cardiovascular risk protein markers of (i) mild iatrogenic hypoglycemia and (ii) severe iatrogenic hypoglycemia followed by rebound hyperglycemia. Methods: Two iatrogenic hypoglycemia studies were compared; firstly, mild hypoglycemia in 18 subjects (10 type 2 diabetes (T2D), 8 controls; blood glucose to 2.8 mmoL/L (50 mg/dL) for 1 h), and secondly, severe hypoglycemia in 46 subjects (23 T2D, 23 controls; blood glucose to <2.2 mmoL/L (<40 mg/dL) transiently followed by intravenous glucose reversal giving rebound hyperglycemia). A SOMAscan assay was used to measure 54 of the 92 cardiovascular protein biomarkers that reflect biomarkers involved in inflammation, cellular metabolic processes, cell adhesion, and immune response and complement activation. Results: Baseline to euglycemia showed no change in any of the proteins measured in the T2D cohort. With severe hypoglycemia, the study controls showed an increase in Angiopoietin 1 (ANGPT1) (p < 0.01) and Dickkopf-1 (DKK1) (p < 0.01), but no changes were seen with mild hypoglycemia. In both the mild and severe hypoglycemia studies, at the point of hypoglycemia, T2D subjects showed suppression of Brother of CDO (BOC) (p < 0.01). At 1 h post-hypoglycemia, the changes in ANGPT1, DKK1, and BOC had resolved, with no additional protein biomarker changes despite rebound hyperglycemia from 1.8 ± 0.1 to 12.2 ± 2.0 mmol/L. Conclusions: Proteomic biomarkers of cardiovascular disease showed changes at hypoglycemia that resolved within 1 h following the hypoglycemic event and with no changes following hyperglycemia rebound, suggesting that any cardiovascular risk increase is due to the hypoglycemia and not due to glucose fluctuation per se.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode

Clementine E. M. Verhulst,Julia I. P. van Heck,Therese W. Fabricius,Rinke Stienstra,Steven Teerenstra,Rory J. McCrimmon,Cees J. Tack,Ulrik Pedersen-Bjergaard,Bastiaan E. de Galan,the Hypo-RESOLVE consortium

DOI: https://doi.org/10.1186/s12933-023-02095-w

IF: 8.949

2024-02-10

Cardiovascular Diabetology

Abstract:Hypoglycaemia has been shown to induce a systemic pro-inflammatory response, which may be driven, in part, by the adrenaline response. Prior exposure to hypoglycaemia attenuates counterregulatory hormone responses to subsequent hypoglycaemia, but whether this effect can be extrapolated to the pro-inflammatory response is unclear. Therefore, we investigated the effect of antecedent hypoglycaemia on inflammatory responses to subsequent hypoglycaemia in humans.

cardiac & cardiovascular systems,endocrinology & metabolism
Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

Andreas Andersen,Jonatan I Bagger,Maria P A Baldassarre,Mikkel B Christensen,Kirsten U Abelin,Jens Faber,Ulrik Pedersen-Bjergaard,Jens J Holst,Tommi B Lindhardt,Gunnar Gislason,Filip K Knop,Tina Vilsbøll

DOI: https://doi.org/10.1530/EJE-21-0232

2021-07-21

Abstract:Objective: Hypoglycemia is associated with an increased risk of cardiovascular disease including cardiac arrhythmias. We investigated the effect of hypoglycemia in the setting of acute glycemic fluctuations on cardiac rhythm and cardiac repolarization in insulin-treated patients with type 2 diabetes compared with matched controls without diabetes. Design: A non-randomized, mechanistic intervention study. Methods: Insulin-treated patients with type 2 diabetes (n = 21, age (mean ± s.d.): 62.8 ± 6.5 years, BMI: 29.0 ± 4.2 kg/m2, HbA1c: 6.8 ± 0.5% (51.0 ± 5.4 mmol/mol)) and matched controls (n = 21, age: 62.2 ± 8.3 years, BMI 29.2 ± 3.5 kg/m2, HbA1c: 5.3 ± 0.3% (34.3 ± 3.3 mmol/mol)) underwent a sequential hyperglycemic and hypoglycemic clamp with three steady-states of plasma glucose: (i) fasting plasma glucose, (ii) hyperglycemia (fasting plasma glucose +10 mmol/L) and (iii) hyperinsulinemic hypoglycemia (plasma glucose < 3.0 mmol/L). Participants underwent continuous ECG monitoring and blood samples for counterregulatory hormones and plasma potassium were obtained. Results: Both groups experienced progressively increasing heart rate corrected QT (Fridericia's formula) interval prolongations during hypoglycemia ((∆mean (95% CI): 31 ms (16, 45) and 39 ms (24, 53) in the group of patients with type 2 diabetes and controls, respectively) with similar increases from baseline at the end of the hypoglycemic phase (P = 0.43). The incidence of ventricular premature beats increased significantly in both groups during hypoglycemia (P = 0.033 and P < 0.0001, respectively). One patient with type 2 diabetes developed atrial fibrillation during recovery from hypoglycemia. Conclusions: In insulin-treated patients with type 2 diabetes and controls without diabetes, hypoglycemia causes clinically significant and similar increases in cardiac repolarization that might increase vulnerability for serious cardiac arrhythmias and sudden cardiac death.
The effect of small increases in blood glucose on insulin secretion and endogenous glucose production in humans

Clinton R. Bruce,Teddy Ang,Jason D. Toms,Giang M. Dao,Jean Liu,Glenn M. Ward,David N. O'Neal,Dale J. Morrison,Greg M. Kowalski

DOI: https://doi.org/10.2337/db24-0388

IF: 7.7

2024-11-14

Diabetes

Abstract:Small glycemic increments (≤0.5 mmol/L) can exert suppressive actions on endogenous glucose production (EGP) however it is unclear if this is an insulin dependent or independent process. Here, we performed a low-rate glucose infusion in control participants without diabetes and in people with type 1 diabetes (T1D) to better understand this phenomenon. Glucose kinetics, hormones and metabolites were measured during a 1 mg/kg/min glucose infusion (90 min) which rapidly increased glucose by ∼0.3...

endocrinology & metabolism
Impact of sweet drink on pituitary response and subject comfort during insulin tolerance test

Tiphaine Carton,Coralie Thiry,Fleur Wolff,Bernard Corvilain,Agnès Burniat

DOI: https://doi.org/10.1038/s41598-024-81401-2

IF: 4.6

2024-12-04

Scientific Reports

Abstract:The insulin tolerance test (ITT) is the gold standard for the diagnosis of cortisol and growth hormone (GH) deficiencies. Once hypoglycemia is detected whether patients should receive carbohydrates to recover faster from hypoglycemia is controversial. The aim of our study was to assess the impact of shortening the duration of hypoglycemia by providing a sugar drink on patient comfort and hormonal responses. This prospective, single-center, crossover, single-blind study enrolled 15 healthy participants. Each subject performed two ITT: one with normal Cola and the other with Cola Zero. Glucose and hormone levels were measured at baseline and after the induction of insulin-induced hypoglycemia. Patient tolerance to ITT was evaluated using reported hypoglycemia side effects, visual analog scale scores, and quality-of-life questionnaire. Normal Cola shortened the period of hypoglycemia (plasma glucose < 40 mg/dl) from 30 to 15 min (p = 0.005), allowing a higher proportion of participants to recover from potentially dangerous values after 45 min (12 vs. 5; p = 0.008). Cola also improved patient comfort, as evaluated using a visual analog scale (VAS score 2.6 vs 3.7, p = 0.016). Sugar did not significantly change the median cortisol and GH peaks. Body mass index was the only factor determining the cortisol peak, independent of the injected insulin dose. The time to reach hormone peaks was similar between the two protocols. Cortisol and GH values were significantly higher at 120 min in the Cola Zero group, suggesting the prolongation of hypothalamic-pituitary stress in the absence of sugar. Our study confirmed that rapid correction of hypoglycemia during ITT improves subject comfort, reduces the duration of hypoglycemia and associated symptoms, while guaranteeing unchanged cortisol and GH peaks.

multidisciplinary sciences
Effect of Hypoglycemia on Heart Rate Variability in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia

Mats Koeneman,Marleen Olde Bekkink,Lian van Meijel,Sebastian Bredie,Bastiaan de Galan

DOI: https://doi.org/10.1177/19322968211007485

2021-04-15

Journal of Diabetes Science and Technology

Abstract:Background: People with impaired awareness of hypoglycemia (IAH) are at elevated risk of severe, potentially hazardous, hypoglycemia and would benefit from a device alerting to hypoglycemia. Heart rate variability (HRV) changes with hypoglycemia due to sympathetic activity. Since IAH is associated with suppressed sympathetic activity, we investigated whether hypoglycemia elicits a measurable change in HRV in patients with T1D and IAH. Method: Eligible participants underwent a modified hyperinsulinemic euglycemic hypoglycemic clamp (glucose nadir, 43.1 ± 0.90 mg/dl), while HRV was measured by a VitalConnect HealthPatch. Measurements of HRV included Root Mean Square of the Successive Differences (RMSSD) and low to high frequency (LF:HF) ratio. Wilcoxon rank-sum test was used for testing within-subject HRV changes. Results: We included 12 participants (8 female, mean age 57 ± 12 years, mean HbA1c 57 ± 5 mmol/mol (7.4 ± 0.4%)). Symptoms increased from 4.0 (1.5-7.0) at euglycemia to 7.5 (5.0-11.0) during hypoglycemia ( P = .003). In response to hypoglycemia, the LF:HF ratio and RMSSD increased when normalized for data obtained during euglycemia (both P < .01). The LF:HF ratio increased in 6 participants (50%) and declined in one other participant (8%). The RMSSD decreased in 3 (25%) and increased in 4 (33%) participants. In 2 patients, no change in HRV could be detected in response to hypoglycemia. Conclusions: This study reveals that hypoglycemia-induced changes in HRV are retained in the majority of people with T1D and IAH, and that these changes can be detected by a wearable device. Real-time HRV seems usable for detection of hypoglycemia in patients with IAH.

English Else
Hypoglycaemia induces a sustained pro‐inflammatory response in people with type 1 diabetes and healthy controls

Clementine E. M. Verhulst,Julia I. P. Heck,Therese W. Fabricius,Rinke Stienstra,Steven Teerenstra,Rory J. McCrimmon,Cees J. Tack,Ulrik Pedersen‐Bjergaard,Bastiaan E. Galan,the Hypo‐RESOLVE consortium,Julia I. P. van Heck,Bastiaan E. de Galan

DOI: https://doi.org/10.1111/dom.15205

2023-07-26

Diabetes, Obesity and Metabolism

Abstract:Aim To determine the duration and the extension of the pro‐inflammatory response to hypoglycaemia both in people with type 1 diabetes and healthy controls. Materials and Methods Adults with type 1 diabetes (n = 47) and matched controls (n = 16) underwent a hyperinsulinaemic‐euglycaemic hypoglycaemic (2.8 ± 0.1 mmoL/L [49.9 ± 2.3 mg/dL]) glucose clamp. During euglycaemia, hypoglycaemia, and 1, 3 and 7 days later, blood was drawn to determine immune cell phenotype, monocyte function and circulating inflammatory markers. Results Hypoglycaemia increased lymphocyte and monocyte counts, which remained elevated for 1 week. The proportion of CD16+ monocytes increased and the proportion of CD14+ monocytes decreased. During hypoglycaemia, monocytes released more tumour necrosis factor‐α and interleukin‐1β, and less interleukin‐10, after ex vivo stimulation. Hypoglycaemia increased the levels of 19 circulating inflammatory proteins, including high sensitive C‐reactive protein, most of which remained elevated for 1 week. The epinephrine peak in response to hypoglycaemia was positively correlated with immune cell number and phenotype, but not with the proteomic response. Conclusions Overall, despite differences in prior exposure to hypoglycaemia, the pattern of the inflammatory responses to hypoglycaemia did not differ between people with type 1 diabetes and healthy controls. In conclusion, hypoglycaemia induces a range of pro‐inflammatory responses that are sustained for at least 1 week in people with type 1 diabetes and healthy controls.

endocrinology & metabolism
A functional polymorphism located in intron of EGFR affects survival outcome of early‐stage non‐small cell lung cancer: 107P

M. Hong,J. Choi,S. K. Do,J. H. Lee,S. Y. Lee,J. Y. Park

DOI: https://doi.org/10.1016/S1556-0864(16)30220-9

IF: 20.121

2016-04-01

Journal of Thoracic Oncology

Abstract:
Effect of diabetic duration on hemorheological properties and platelet aggregation in streptozotocin-induced diabetic rats

Eunseop Yeom,Hyeokjun Byeon,Sang Joon Lee

DOI: https://doi.org/10.1038/srep21913

2016-02-22

Abstract:Diabetes mellitus with abnormal glucose concentration is associated with changes in hemorheological properties, endothelial function, and platelets hyperactivity. Disturbances may significantly be responsible for diabetes-related vascular complications. In this study, hemorheological and hemodynamic properties were measured according to diabetic duration after streptozotocin treatment in rats. For ex vivo measurements, an extracorporeal model was adopted. Flow rate and blood viscosity were measured using a microfluidic device. Erythrocyte aggregation and morphological parameters of erythrocytes were measured by modified erythrocyte sedimentation rate and the phase-contrast holography under in vitro conditions. The platelet aggregation and mean pressure in the femoral artery were estimated under ex vivo conditions. Hemorheological properties including blood viscosity, erythrocyte aggregation and shape parameters for the control group are significantly different with those for diabetic groups. The changes with respect to diabetic duration were relatively unnoticeable. However, the platelet aggregation is strongly dependent on the diabetic duration. Based on these results, hyperglycemia exposure may induce hemorheological variations in early stages of diabetes mellitus. High platelet aggregation may become more pronounced according to the diabetic duration caused by variations in hemorheological properties resulting in endothelial dysfunction. This study would be helpful in understanding the effects of diabetic duration on biophysical properties.
[Evaluation of islet beta cell function in subjects with normal glucose tolerance, impaired glucose regulation, and type 2 diabetes mellitus].

Juan Liu,Yan-bing Li,Hong Shao,Yue-xia Li,Yong-hong Yuan,Yi-Bin Xiao,Jian-ping Weng

DOI: https://doi.org/10.3760/j:issn:0376-2491.2007.18.009

2007-01-01

Abstract:In the stage of IGR, an evident deficit in phasic insulin secretion after glucose load and a decreasing HOMAbeta are exhibited. In addition to this, qualitative decrease of insulin secretion appears in the DM stage. AIR is a reliable index of isletbeta cell function. DeltaI30/DeltaG30 is an alternative one in the subjects with NGT and IGR. But it should be adjusted by IR in diabetic patients.
Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement

Diana A. Gorog,Richard C. Becker

DOI: https://doi.org/10.1007/s11239-020-02170-z

2020-06-11

Journal of Thrombosis and Thrombolysis

Abstract:Abstract Studies using whole blood platelet aggregometry as a laboratory research tool, provided important insights into the mechanism and modulators of platelet aggregation. Subsequently, a number of point-of-care (POC) platelet function tests (PFTs) were developed for clinical use, based on the concept that an individual’s thrombotic profile could be assessed in vitro by assessing the response to stimulation of platelet aggregation by specific, usually solo agonists such as adenosine diphosphate (ADP), collagen and thrombin. However, adjusting antiplatelet medication in order to improve the results of such POC PFTs has not translated into a meaningful reduction in cardiovascular events, which may be attributable to important differences between the POC PFT techniques and in vivo conditions, including patient-to-patient variability. Important limitations of most tests include the use of citrate-anticoagulated blood. Citrate directly and irreversibly diminishes platelet function and even after recalcification, it may result in altered platelet aggregation in response to ADP, epinephrine or collagen, and interfere with thrombin generation from activated platelets. Furthermore, most tests do not employ flowing blood and therefore do not assess the effect of high shear forces on platelets that initiate, propagate and stabilize arterial thrombi. Finally, the effect of endogenous thrombolysis, due to fibrinolysis and dislodgement, which ultimately determines the outcome of a thrombotic stimulus, is mostly not assessed. In order to accurately reflect an individual’s predisposition to arterial thrombosis, future tests of thrombotic status which overcome these limitations should be used, to improve cardiovascular risk prediction and to guide pharmacotherapy.

cardiac & cardiovascular systems,peripheral vascular disease,hematology

66-year-old woman with painless jaundice.

Postprandial platelet aggregation: effects of different meals and glycemic index

Effects of insulin on platelet and leukocyte activity in whole blood.

The Effect of Hyperglycaemia on the Islet Β-Cell Responsiveness in Type 2 Diabetic Patients

A randomised controlled study of high intensity exercise as a dishabituating stimulus to improve hypoglycaemia awareness in people with type 1 diabetes: a proof-of-concept study

Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

Type 2 Diabetes: Platelets and Long-Term Metabolic Control as Estimated from Glycosylated Haemoglobin (HbA1c)

Epidemiology of chronic pain and critical issues on opioid use

Real‐life hypoglycaemia partially blunts the inflammatory response to experimental hypoglycaemia in people with type 1 diabetes

Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]

Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers

The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode

Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

The effect of small increases in blood glucose on insulin secretion and endogenous glucose production in humans

Impact of sweet drink on pituitary response and subject comfort during insulin tolerance test

Effect of Hypoglycemia on Heart Rate Variability in People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia

Hypoglycaemia induces a sustained pro‐inflammatory response in people with type 1 diabetes and healthy controls

A functional polymorphism located in intron of EGFR affects survival outcome of early‐stage non‐small cell lung cancer: 107P

Effect of diabetic duration on hemorheological properties and platelet aggregation in streptozotocin-induced diabetic rats

[Evaluation of islet beta cell function in subjects with normal glucose tolerance, impaired glucose regulation, and type 2 diabetes mellitus].

Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement